Postmarketing Studies On Abuse-Deterrent Opioids Could Get New Look

Data sources and methodologies to evaluate real-world effects of abuse-deterrent formulations will be focus of US FDA public meeting in July; value and feasibility of assessing the public health effects of such products more broadly is up for discussion.

Opioid abuse epidemic concept

The scientific value of currently studied outcomes with abuse-deterrent opioid formulations, and whether new or different outcomes are needed, will be up for discussion at a US FDA meeting on methods for assessing the real-world effects of such products.

The agency will hold a public workshop July 10-11 on data and methods for evaluating the postmarketing impact of opioids...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet